Efficacy of Paclitaxel and Cetuximab in Recurrent/Metastatic Oral Cancer Cases Following Superselective Intraarterial Chemoradiotherapy: A Retrospective Cohort Study
KANAME SAKUMA, TOMOYUKI KII, TOKO MACHIDA, YOSUKE KIKUCHI, MASAKI YODA, SHUJI TOYA, AKIRA TANAKA · 2024
Read Efficacy of Paclitaxel and Cetuximab in Recurrent/Metastatic Oral Cancer Cases Following Superselective Intraarterial Chemoradiotherapy: A Retrospective Cohort Study by KANAME SAKUMA, TOMOYUKI KII, TOKO MACHIDA, YOSUKE KIKUCHI, MASAKI YODA, SHUJI TOYA, AKIRA TANAKA (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11534039.txt.
Description
When mouth cancer returns after targeted artery-delivered chemo and radiation, options shrink. Kaname Sakuma and co-authors review nine such patients treated with a two-drug weekly regimen: paclitaxel plus cetuximab. All had already received the intensive first treatment over six to nine weeks, and their cancer came back or spread within six months.
Four of the nine patients responded, a rate of about 44 percent, and eight had their disease controlled for a time. Median time without growth was seven months, and median survival was eleven months. Side effects centered on lowered blood counts, plus a skin rash in some patients. The authors judge the results in line with other second-line choices. They note the regimen's side effects can be managed, which matters for patients with few options left.
Catalog record
| CREATOR | KANAME SAKUMA, TOMOYUKI KII, TOKO MACHIDA, YOSUKE KIKUCHI, MASAKI YODA, SHUJI TOYA, AKIRA TANAKA |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |